# MGD019 DART® Protein in Unresectable/Metastatic Cancer

> **NCT03761017** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 162 (actual)

## Conditions studied

- Squamous Cell Non Small Cell Lung Cancer
- Prostate Cancer Metastatic
- Cutaneous Melanoma
- Colorectal Cancer
- Advanced Cancer
- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** Lorigerlimab

## Key facts

- **NCT ID:** NCT03761017
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2024-08-29
- **Final completion:** 2025-01-27
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761017, "MGD019 DART® Protein in Unresectable/Metastatic Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03761017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*